Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an inducement equity award to a newly hired employee under its 2022 Inducement Stock Incentive Plan. The award consists of 1,200 restricted stock units (RSUs), granted on May 31, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to the employee’s continued service with Karyopharm.

AI-generated analysis. Not financial advice.

News Market Reaction – KPTI

-6.01%

29 alerts

-6.01% News Effect

+2.3% Peak Tracked

-11.9% Trough Tracked

-$14M Valuation Impact

$223.57M Market Cap

0.5x Rel. Volume

On the day this news was published, KPTI declined 6.01%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -11.9% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $223.57M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

RSU grant size: 1,200 RSUs Vesting period: 3 years Annual vesting rate: 33 1/3% +5 more

8 metrics

RSU grant size 1,200 RSUs Inducement grant to one new employee as of May 31, 2026

Vesting period 3 years RSUs vest over three consecutive anniversaries of the Grant Date

Annual vesting rate 33 1/3% Portion of RSU award vesting on each anniversary over three years

Current price $9.10 Price before news; about 17.2% below 52-week high

52-week range $3.6503–$10.99 Low to high range prior to this announcement

Registered resale shares 8,843,036 shares Shares covered by effective registration statement filed May 4, 2026

Private placement proceeds $30 million Gross proceeds from March 2026 private placement tied to registration

Ownership cap 9.99% Beneficial ownership limit on warrant exercises in registration

Market Reality Check

Price: $9.23 Vol: Volume 290,680 vs 20-day ...

low vol

$9.23 Last Close

Volume Volume 290,680 vs 20-day average 461,234; relative volume at 0.63 ahead of this filing-style news. low

Technical Price $9.10 is trading above the 200-day MA of $7.08 prior to this announcement.

Peers on Argus

KPTI was near-flat at -0.11% while only one peer in the momentum list (MAIA) sho...

1 Down

KPTI was near-flat at -0.11% while only one peer in the momentum list (MAIA) showed downward activity; broader biotech peers had mixed moves, indicating this item was company-specific rather than a sector-wide driver.

Common Catalyst Peer news today focused on clinical trial progress and regulatory submissions, contrasting with KPTI’s routine equity inducement grant.

Historical Context

5 past events · Latest: May 28 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 28	Conference participation	Neutral	+1.4%	Management slated for Jefferies healthcare conference fireside chat with webcast access.
May 14	Earnings & trials	Positive	+0.6%	Q1 2026 results, revenue guidance reaffirmation, and key Phase 3 trial milestones.
May 12	Investor conferences	Neutral	+1.2%	Participation in multiple May 2026 investor conferences via fireside chats.
May 07	Earnings date set	Neutral	-1.9%	Announcement of timing and webcast details for Q1 2026 earnings release.
Apr 21	ASCO late-breaker	Positive	+2.6%	Phase 3 SENTRY myelofibrosis data selected for late-breaking oral ASCO 2026 slot.

Pattern Detected

Recent KPTI news, especially earnings and clinical milestones, more often coincided with positive next-day moves, while scheduling updates drew a mixed response.

Recent Company History

Over the last few months, Karyopharm has highlighted conference participation, financial results, and advancing late-stage trials. Earnings and clinical updates on May 14, 2026 and the Phase 3 SENTRY ASCO selection on April 21, 2026 coincided with positive price reactions, suggesting investors focused on revenue and pivotal data. Scheduling releases, such as the upcoming earnings date on May 7, 2026, saw a negative move. Today’s small RSU inducement grant fits into ongoing equity-based compensation activity rather than a major strategic shift.

Regulatory & Risk Context

Active S-3 Shelf · $30 million

Shelf Active

Active S-3 Shelf Registration 2026-05-04

$30 million registered capacity

An effective S-3 registration filed on May 4, 2026 covers the resale of up to 8,843,036 shares from a March 2026 private placement that generated about $30 million in gross proceeds. The company receives no proceeds from these resales, which are subject to a 9.99% beneficial ownership cap on warrant exercises.

Market Pulse Summary

The stock moved -6.0% in the session following this news. A negative reaction despite this routine i...

Analysis

The stock moved -6.0% in the session following this news. A negative reaction despite this routine inducement grant would fit a pattern where even neutral events sometimes coincided with downside, as seen around the earnings date announcement on May 7, 2026. The grant of 1,200 RSUs under Nasdaq Listing Rule 5635(c)(4) is small compared with previously disclosed share pools and an effective registration for 8,843,036 resale shares, but broader concerns tied to that overhang or recent insider stock sales could amplify selling pressure.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4)

3 terms

restricted stock units financial

"the Company granted 1,200 restricted stock units (RSUs) to one newly-hired employee"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"1,200 restricted stock units (RSUs) to one newly-hired employee"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 1,200 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of May 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO^® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO^® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302786006.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What inducement grant did Karyopharm Therapeutics (KPTI) announce on June 1, 2026?

Karyopharm Therapeutics announced an inducement grant of 1,200 restricted stock units (RSUs) to one newly hired employee. According to Karyopharm, the grant was made under its 2022 Inducement Stock Incentive Plan as an employment inducement.

When was the Karyopharm Therapeutics (KPTI) inducement RSU grant effective?

The inducement RSU grant became effective on May 31, 2026, designated as the grant date. According to Karyopharm, this date governs the vesting schedule, with RSUs vesting on each of the three consecutive anniversaries of the grant date.

How do the 1,200 RSUs granted by Karyopharm (KPTI) vest over time?

The 1,200 RSUs vest in three equal annual installments of 33 1/3% each year. According to Karyopharm, vesting occurs on each of the three anniversaries of the May 31, 2026 grant date, subject to continued service.

What conditions apply to the vesting of Karyopharm Therapeutics (KPTI) inducement RSUs?

Vesting of the RSUs requires the employee’s continued service with Karyopharm or as another service provider. According to Karyopharm, RSUs vest only if the individual remains in service through each applicable vesting date.

Under which plan were the 1,200 Karyopharm (KPTI) inducement RSUs granted?

The RSUs were granted under Karyopharm’s 2022 Inducement Stock Incentive Plan, as amended. According to Karyopharm, this plan supports equity awards used as a material inducement for new employees joining the company.

How is Nasdaq Listing Rule 5635(c)(4) related to Karyopharm’s (KPTI) inducement RSU grant?

Karyopharm stated the RSU grant was made in accordance with Nasdaq Listing Rule 5635(c)(4). According to Karyopharm, the award serves as a material inducement for the new employee to enter into employment with the company.